Key result
Fatty liver infiltration linked to ~430% greater metabolic syndrome odds in morbidly obese patients.
Why the study?
Are CT-measured visceral fat area and fatty liver infiltration associated with metabolic syndrome in morbidly obese patients?
Cross-Sectional (n=100)
Are CT-measured visceral fat area and fatty liver infiltration associated with metabolic syndrome in morbidly obese patients?
CT-measured visceral adiposity and hepatic fatty infiltration are better markers for metabolic syndrome than BMI and waist circumference in morbidly obese patients.
Answers are grounded in this paper and cite their sources.
May support CT visceral fat and liver fat measures for metabolic syndrome assessment in morbid obesity; leaves open validation against BMI in prospective studies.
BACKGROUND: Despite its widespread clinical use, both body mass index (BMI) and waist circumference have been reported as inaccurate methods to measure abdominal obesity. The main objective of this study was to determine the relation between visceral fat area and fatty liver infiltration with the expression of metabolic syndrome (MS) in morbidly obese patients. METHODS: We recruited a random selection of 100 morbidly obese patients on pre-operative evaluation for bariatric surgery. A pre-operative CT slice at L4-L5 level, was performed to measure visceral fat and at T12 level to measure hepatic attenuation. RESULTS: Patients with MS had lower hepatic attenuation values (median 49.9 vs 55.5HU; p = .018) and had more VAT (242 vs 172 cm(2);p = .001). Conventional measures (BMI: p = .729 and waist circumference: p = .356), were not useful in discriminating morbidly obese patients with MS. By multivariable logistic regression, fatty liver infiltration (OR = 5.3; p = .03) and age (OR = 1.08; p = .04) were the only factors independently related to the presence of MS. MS prevalence was 100%, 71% and 55%, respectively for patients with both fatty liver and visceral adiposity; one; or none of this findings (AUC - .715; p = .016). CONCLUSION: CT scan seems to measure 2 important markers of MS: visceral adiposity and hepatic fatty infiltration. In morbidly obese patients, both visceral adiposity and hepatic fatty infiltration increase the risk for the presence of MS.
No takes yet. Share an insight, caveat, or question.
Faria et al. (2015) conducted a cross-sectional in Morbid obesity (n=100). Fatty liver infiltration and visceral adiposity vs. Absence of fatty liver infiltration and visceral adiposity was evaluated on Presence of metabolic syndrome (OR 5.3, p=.03). Fatty liver infiltration and visceral adiposity were associated with the presence of metabolic syndrome in morbidly obese patients.
Synapse has enriched 10 related papers. Consider them for comparative context: